ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

ClinicalTrials.gov ID: NCT02280252

Public ClinicalTrials.gov record NCT02280252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Response, Resistance and Metastasis of Locally Advanced Breast Cancer (LABC, Stage 2B-3C) in a Multiethnic Cohort: A Phase II International Multicentric Study of Concurrent Paclitaxel and Radiation

Study identification

NCT ID
NCT02280252
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NYU Langone Health
Other
Enrollment
69 participants

Conditions and interventions

Conditions

Interventions

  • Paclitaxel Drug
  • Radiation therapy Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2005
Primary completion
Dec 19, 2018
Completion
Dec 19, 2018
Last update posted
Nov 22, 2020

2005 – 2018

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
NYU Langone Medical Center New York New York 10016

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02280252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2020 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02280252 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →